Oncotarget

Research Papers:

Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin’s lymphomas

Rita Lh Yim _, Kwan Yeung Wong, Yok Lam Kwong, Florence Loong, Chung Ying Leung, Raymond Chu, William W. Lam, Pak Kwan Hui, Raymond Lai and Chor Sang Chin

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:9770-9782. https://doi.org/10.18632/oncotarget.2390

Metrics: PDF 1270 views  |   HTML 2205 views  |   ?  


Abstract

Rita Lh Yim1, Kwan Yeung Wong1, Yok Lam Kwong1, Florence Loong2, Chung Ying Leung3, Raymond Chu4, William Wai Lung Lam5, Pak Kwan Hui6, Raymond Lai7, Chor Sang Chim1

1Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong

2Department of Pathology, Queen Mary Hospital, Hong Kong

3Department of Pathology, United Christian Hospital, Hong Kong

4Department of Pathology, Pamela Youde Nethersole Eastern Hospital, Hong Kong

5Department of Pathology, Princess Margaret Hospital, Hong Kong

6Department of Pathology, Kwong Wah Hospital, Hong Kong

7Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada

Correspondence to:

Chor-Sang Chim, e-mail: jcschim@hku.hk

Key Words: tumor suppressive microRNA, hypermethylation, miR-155-3p, mantle cell lymphoma, non-Hodgkin’s lymphoma

Received: July 08, 2014     Accepted: August 23, 2014     Published: November 11, 2014

ABSTRACT

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin’s lymphoma (NHL). In cancers, tumor suppressive microRNAs may be silenced by DNA hypermethylation. By microRNA profiling of representative EBV-negative MCL cell lines before and after demethylation treatment, miR-155-3p was found significantly restored. Methylation-specific PCR, verified by pyrosequencing, showed complete methylation of miR-155-3p in one MCL cell line (REC-1). 5-aza-2′-deoxycytidine treatment of REC-1 led to demethylation and re-expression of miR-155-3p. Over-expression of miR-155-3p led to increased sub-G1 apoptotic cells and reduced cellular viability, demonstrating its tumor suppressive properties. By luciferase assay, lymphotoxin-beta (LT-β) was validated as a miR-155-3p target. In 31 primary MCL, miR-155-3p was found hypermethylated in 6(19%) cases. To test if methylation of miR-155-3p was MCL-specific, miR-155-3p methylation was tested in an additional 191 B-cell, T-cell and NK-cell NHLs, yielding miR-155-3p methylation in 66(34.6%) including 36(27%) non-MCL B-cell, 24(53%) T-cell and 6(46%) of NK-cell lymphoma. Moreover, in 72 primary NHL samples with RNA, miR-155-3p methylation correlated with miR-155-3p downregulation (p=0.024), and LT-β upregulation (p=0.043). Collectively, miR-155-3p is a potential tumor suppressive microRNA hypermethylated in MCL and other NHL subtypes. As miR-155-3p targets LT-β, which is an upstream activator of the non-canonical NF-kB signaling, miR-155-3p methylation is potentially important in lymphomagenesis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2390